Lars Hyveled-Nielsen

SANOS Bioscience A/S is a Danish privately owned biotechnology company. Their business is to develop novel treatments for osteoporosis and other skeletal wasting diseases. It was founded in 2003 around patented and proprietary inventions from the Nordic Bioscience Group. This knowledge base includes a profound insight in the biology of skeletal tissue in health, molecular targets, biologicals, and lead compounds. SANOS is focused on the clinical development of SAN-134, an injectable formulation of the intestinal hormone glucagon-like peptide-2, GLP-2 for treatment of diseases with accelerated bone loss, such as osteoporosis. SANOS Bioscience A/S is headquarterd in Copenhagen, Denmark.